2024-09-03 - Analysis Report
## Gilead Sciences (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences is a biopharmaceutical company that develops and commercializes treatments for life-threatening diseases.

**1. Performance Comparison:**

* **GILD Cumulative Return:** 14.51%
* **S&P 500 (VOO) Cumulative Return:** 89.66%
* **Performance Gap:** -75.15% 
* **Relative Gap:** 15.83% (This indicates that GILD's performance is currently at the 15.83% percentile compared to its historical performance relative to the S&P 500)

Gilead Sciences has significantly underperformed the S&P 500 over the period analyzed, with a 75.15% gap in performance.

**2. Recent Price Movements:**

* **Closing Price:** $79.0
* **5-Day Moving Average:** $78.19
* **20-Day Moving Average:** $75.47
* **60-Day Moving Average:** $71.78

The current price is above all three moving averages, indicating potential upward momentum.

**3. Technical Indicators:**

* **RSI:** 87.42 (Overbought territory)
* **PPO:** 0.4 (Positive signal)
* **Delta_Previous_Relative_Divergence:** -5.9 (Negative, indicating potential short-term decline)
* **Expected Return:** 21.27% (Max 5-year expected return)

The RSI indicates an overbought condition, potentially suggesting a short-term correction. However, the PPO is positive, suggesting potential for continued upward movement. The negative Delta_Previous_Relative_Divergence suggests a short-term downward trend. The expected return of 21.27% is promising.

**4. Recent Earnings & Outlook:**

| Date       | EPS       | Revenue       |
|------------|------------|---------------|
| 2024-08-08 | 1.29      | 6.95 B$      |
| 2024-05-08 | -3.34      | 6.69 B$      |
| 2023-11-07 | 1.75      | 7.05 B$      |
| 2023-08-04 | 0.84      | 6.60 B$      |
| 2024-08-08 | 0.84      | 6.60 B$      |

The most recent earnings report (2024-08-08) showed EPS of 1.29, exceeding analysts' expectations. Revenue came in at $6.95B, slightly above expectations. This positive earnings surprise could indicate a strong underlying business performance and potentially support the stock price. 

**5. Summary:**

Gilead Sciences has underperformed the broader market in recent times but has shown positive earnings performance in the most recent quarter. The stock's price is currently above its moving averages, indicating potential upward momentum. However, technical indicators suggest a potential short-term correction, with the RSI showing overbought conditions and Delta_Previous_Relative_Divergence showing a negative trend. The positive PPO and expected return of 21.27% remain encouraging.  It is important to consider these factors and conduct further analysis before making any investment decisions.

**6. Conclusion:**

Gilead Sciences is facing a challenging market environment, and its performance has lagged behind the S&P 500. However, recent positive earnings and a potential for future growth due to its strong product pipeline may make it an attractive investment for long-term investors. However, the stock's current overbought condition and potential for short-term correction should be considered. A more detailed analysis and monitoring of future earnings reports and market conditions are necessary for a comprehensive assessment of the stock's potential. 
